Associations of diabetes, hypertension and obesity with COVID-19 mortality: a systematic review and meta-analysis

Abstract

IntroductionDespite a growing body of scholarly research on the risks of severe COVID-19 associated with diabetes, hypertension and obesity, there is a need for estimating pooled risk estimates with adjustment for confounding effects. We conducted a systematic review and meta-analysis to estimate the pooled adjusted risk ratios of diabetes, hypertension and obesity on COVID-19 mortality.MethodsWe searched 16 literature databases for original studies published between 1 December 2019 and 31 December 2020. We used the adapted Newcastle-Ottawa Scale to assess the risk of bias. Pooled risk ratios were estimated based on the adjusted effect sizes. We applied random-effects meta-analysis to account for the uncertainty in residual heterogeneity. We used contour-funnel plots and Egger’s test to assess possible publication bias.ResultsWe reviewed 34 830 records identified in literature search, of which 145 original studies were included in the meta-analysis. Pooled adjusted risk ratios were 1.43 (95% CI 1.32 to 1.54), 1.19 (95% CI 1.09 to 1.30) and 1.39 (95% CI 1.27 to 1.52) for diabetes, hypertension and obesity (body mass index ≥30 kg/m2) on COVID-19 mortality, respectively. The pooled adjusted risk ratios appeared to be stronger in studies conducted before April 2020, Western Pacific Region, low- and middle-income countries, and countries with low Global Health Security Index scores, when compared with their counterparts.ConclusionsDiabetes, hypertension and obesity were associated with an increased risk of COVID-19 mortality independent of other known risk factors, particularly in low-resource settings. Addressing these chronic diseases could be important for global pandemic preparedness and mortality prevention.PROSPERO registration numberCRD42021204371.

Assessment of COVID-19 risk factors of early and long-term mortality with prediction models of clinical and laboratory variables

“…The natural course of COVID-19 infection varies depending on the patient’s individual characteristics, such as age, comorbidities, and immune system status. Clinical variables, such as diabetes and hypertension, have been reported to be important factors influencing the course of COVID-19 [ 25 ]. In our analysis, we confirmed the significance of diabetes and atrial fibrillation on patient outcomes.…”

Potential associations of selected polymorphic genetic variants with COVID-19 disease susceptibility and severity

“…In addition to the signs of severe pulmonary disease, the poor prognosis of hospitalized patients is predominantly indicated by laboratory data reflecting an overreaction of the immune system to viral infection. The already established factors affecting the severity of acute COVID-19 include older age, overweight status, and comorbidities (e.g., diabetes) [1][2][3][4]. The currently used pharmacological agents to treat COVID-19 have questionable effects in severe cases, and positive results are mostly observed at the initial stage of this disease (see) [5][6][7][8][9]).…”

SARS-CoV-2 Spike Protein Enhances Carboxypeptidase Activity of Angiotensin-Converting Enzyme 2

“…It is not yet clear what factors determine COVID-19 severity. In this regard, comorbidities such as cardiorenal disease, chronic obstructive pulmonary disease, obesity, diabetes, and hypertension correlate with COVID-19 severity [ 1 ]. Angiotensin-converting enzyme 2 (ACE2) is the receptor for SARS-CoV-2 and other coronaviruses (SARS-CoV, HCoV-NL63) [ 2 , 3 ].…”